Merck can’t prove its Alzheimer’s drug works, yet, but it did just explain why it’s spending a fortune on PhIII
Investigators for Merck $MRK have very carefully outlined all the early-stage human and animal data they can muster for their Alzheimer’s drug verubecestat. Now in an ambitious Phase III due to read out in mid-2017, tests proved that the BACE drug can successfully target one of the key biomarkers for the disease.
They just don’t have any convincing data to show whether it will actually make a difference in patients’ cognitive abilities, or improve their ability to function in their daily lives.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.